ABBVAbbVieRunning, no new patients
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Hidradenitis Suppurativa
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 210 (final count)
- Started
- Dec 28, 2021
- Main results expected
- Dec 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR)
Measured over: Week 16
Number of Participants with Adverse Events (AEs)
Measured over: Up to Approximately Week 68
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05139602 · record last updated 2026-02-13 · checked 2026-11-09 15:47 UTC